Article Contents ::
- 1 Details About Generic Salt :: Hepatiti
- 2 Main Medicine Class:: Immune serum
- 3
(hep-uh-TIGHT-iss)
BayHep B
Injection
217 IU/mL
Nabi HB
Injection
312 IU/mL
Bayhep B
Class: Immune serum
Action Directly neutralizes hepatitis B virus.
Indications For passive, transient prevention of hepatitis B infection after viral exposure via needlestick or mucous membrane contact; prevention of hepatitis B in infants born to HBsAg-positive mothers. Most effective when used within 7 days of exposure.
Contraindications None well documented.
Route/Dosage
Adults and Children: IM 0.06 mL/kg (usually 3 to 5 mL). Administer as soon as possible after exposure and repeat 28 to 30 days later. Newborns of HBsAg-Positive Mothers: IM 0.5 mL. Administer first HBIG dose as soon as possible, preferably < 12 hr after birth. Also give hepatitis B vaccine. If hepatitis B vaccine is declined, repeat HBIG at 3 and 6 mo of age.
Interactions
Anticoagulants: Give HBIG with caution to people receiving anticoagulant therapy. Vaccines: To avoid inactivating vaccines containing live viruses (except measles vaccine) or bacteria, give live vaccines 3 mo after HBIG.
Lab Test Interferences None well documented.
Adverse Reactions OTHER Local pain and tenderness at injection site; urticaria; angioedema; anaphylactic reactions.
Precautions
Pregnancy: Category C. Lactation: Undetermined.
PATIENT CARE CONSIDERATIONS
Administration/Storage
Inspect solution for particulate matter and discoloration before administration.
Administer IM, preferably in gluteal or deltoid muscle in adults and children. In newborns, administer IM in anterolateral thigh. Do not give IV.
Always record manufacturer’s name and lot number on vial in patient’s permanent record file along with date of administration, name and title of person administering injection.
Refrigerate vials. Do not freeze.
Assessment/Interventions
Obtain complete history, including drug history and any known allergies.
Check patient’s immunization history to verify that administration regimen is being followed.
Review patient’s medical history for history of serious adverse reactions to previous dose of HBIG.
Monitor for hypersensitivity or anaphylaxis. Epinephrine should always be available to counteract any possible reactions.
OVERDOSAGE: SIGNS & SYMPTOMS
Pain, tenderness
Patient/Family Education
Instruct parent to vaccinate all at-risk infants as soon after birth as possible and again at 3 mo.
Instruct patient that therapy is useful as postexposure prophylaxis as soon after exposure as possible (preferably within 7 days.)
Provide patient or parent with immunization history record and record this injection in patient’s medical records.
Instruct patient to give analgesic for local pain. Avoid giving aspirin to children.
Inform parent or patient of schedule for vaccination program if necessary.
- 4 Drugs Class ::
- 5 Disclaimer ::
- 6 The Information available on this site is for only Informational Purpose , before any use of this information please consult your Doctor .Price of the drugs indicated above may not match to real price due to many possible reasons may , including local taxes etc.. These are only approximate indicative prices of the drug.
Details About Generic Salt :: Hepatiti
| (hep-uh-TIGHT-iss) |
| BayHep B |
| Injection |
| 217 IU/mL |
| Nabi HB |
| Injection |
| 312 IU/mL |
| Bayhep B |
| Class: Immune serum |
Action Directly neutralizes hepatitis B virus.
Indications For passive, transient prevention of hepatitis B infection after viral exposure via needlestick or mucous membrane contact; prevention of hepatitis B in infants born to HBsAg-positive mothers. Most effective when used within 7 days of exposure.
Contraindications None well documented.
Route/Dosage
Adults and Children: IM 0.06 mL/kg (usually 3 to 5 mL). Administer as soon as possible after exposure and repeat 28 to 30 days later. Newborns of HBsAg-Positive Mothers: IM 0.5 mL. Administer first HBIG dose as soon as possible, preferably < 12 hr after birth. Also give hepatitis B vaccine. If hepatitis B vaccine is declined, repeat HBIG at 3 and 6 mo of age.
Interactions
Anticoagulants: Give HBIG with caution to people receiving anticoagulant therapy. Vaccines: To avoid inactivating vaccines containing live viruses (except measles vaccine) or bacteria, give live vaccines 3 mo after HBIG.
Lab Test Interferences None well documented.
Adverse Reactions OTHER Local pain and tenderness at injection site; urticaria; angioedema; anaphylactic reactions.
Precautions
Pregnancy: Category C. Lactation: Undetermined.
|
PATIENT CARE CONSIDERATIONS |
|
Administration/Storage
- Inspect solution for particulate matter and discoloration before administration.
- Administer IM, preferably in gluteal or deltoid muscle in adults and children. In newborns, administer IM in anterolateral thigh. Do not give IV.
- Always record manufacturer’s name and lot number on vial in patient’s permanent record file along with date of administration, name and title of person administering injection.
- Refrigerate vials. Do not freeze.
Assessment/Interventions
- Obtain complete history, including drug history and any known allergies.
- Check patient’s immunization history to verify that administration regimen is being followed.
- Review patient’s medical history for history of serious adverse reactions to previous dose of HBIG.
- Monitor for hypersensitivity or anaphylaxis. Epinephrine should always be available to counteract any possible reactions.
| OVERDOSAGE: SIGNS & SYMPTOMS |
| |
Pain, tenderness |
|
Patient/Family Education
- Instruct parent to vaccinate all at-risk infants as soon after birth as possible and again at 3 mo.
- Instruct patient that therapy is useful as postexposure prophylaxis as soon after exposure as possible (preferably within 7 days.)
- Provide patient or parent with immunization history record and record this injection in patient’s medical records.
- Instruct patient to give analgesic for local pain. Avoid giving aspirin to children.
- Inform parent or patient of schedule for vaccination program if necessary.
Drugs Class ::
| (hep-uh-TIGHT-iss) |
| BayHep B |
| Injection |
| 217 IU/mL |
| Nabi HB |
| Injection |
| 312 IU/mL |
| Bayhep B |
| Class: Immune serum |
Action Directly neutralizes hepatitis B virus.
Indications For passive, transient prevention of hepatitis B infection after viral exposure via needlestick or mucous membrane contact; prevention of hepatitis B in infants born to HBsAg-positive mothers. Most effective when used within 7 days of exposure.
Contraindications None well documented.
Route/Dosage
Adults and Children: IM 0.06 mL/kg (usually 3 to 5 mL). Administer as soon as possible after exposure and repeat 28 to 30 days later. Newborns of HBsAg-Positive Mothers: IM 0.5 mL. Administer first HBIG dose as soon as possible, preferably < 12 hr after birth. Also give hepatitis B vaccine. If hepatitis B vaccine is declined, repeat HBIG at 3 and 6 mo of age.
Interactions
Anticoagulants: Give HBIG with caution to people receiving anticoagulant therapy. Vaccines: To avoid inactivating vaccines containing live viruses (except measles vaccine) or bacteria, give live vaccines 3 mo after HBIG.
Lab Test Interferences None well documented.
Adverse Reactions OTHER Local pain and tenderness at injection site; urticaria; angioedema; anaphylactic reactions.
Precautions
Pregnancy: Category C. Lactation: Undetermined.
|
PATIENT CARE CONSIDERATIONS |
|
Administration/Storage
- Inspect solution for particulate matter and discoloration before administration.
- Administer IM, preferably in gluteal or deltoid muscle in adults and children. In newborns, administer IM in anterolateral thigh. Do not give IV.
- Always record manufacturer’s name and lot number on vial in patient’s permanent record file along with date of administration, name and title of person administering injection.
- Refrigerate vials. Do not freeze.
Assessment/Interventions
- Obtain complete history, including drug history and any known allergies.
- Check patient’s immunization history to verify that administration regimen is being followed.
- Review patient’s medical history for history of serious adverse reactions to previous dose of HBIG.
- Monitor for hypersensitivity or anaphylaxis. Epinephrine should always be available to counteract any possible reactions.
| OVERDOSAGE: SIGNS & SYMPTOMS |
| |
Pain, tenderness |
|
Patient/Family Education
- Instruct parent to vaccinate all at-risk infants as soon after birth as possible and again at 3 mo.
- Instruct patient that therapy is useful as postexposure prophylaxis as soon after exposure as possible (preferably within 7 days.)
- Provide patient or parent with immunization history record and record this injection in patient’s medical records.
- Instruct patient to give analgesic for local pain. Avoid giving aspirin to children.
- Inform parent or patient of schedule for vaccination program if necessary.
Indications for Drugs ::
| (hep-uh-TIGHT-iss) |
| BayHep B |
| Injection |
| 217 IU/mL |
| Nabi HB |
| Injection |
| 312 IU/mL |
| Bayhep B |
| Class: Immune serum |
Action Directly neutralizes hepatitis B virus.
Indications For passive, transient prevention of hepatitis B infection after viral exposure via needlestick or mucous membrane contact; prevention of hepatitis B in infants born to HBsAg-positive mothers. Most effective when used within 7 days of exposure.
Contraindications None well documented.
Route/Dosage
Adults and Children: IM 0.06 mL/kg (usually 3 to 5 mL). Administer as soon as possible after exposure and repeat 28 to 30 days later. Newborns of HBsAg-Positive Mothers: IM 0.5 mL. Administer first HBIG dose as soon as possible, preferably < 12 hr after birth. Also give hepatitis B vaccine. If hepatitis B vaccine is declined, repeat HBIG at 3 and 6 mo of age.
Interactions
Anticoagulants: Give HBIG with caution to people receiving anticoagulant therapy. Vaccines: To avoid inactivating vaccines containing live viruses (except measles vaccine) or bacteria, give live vaccines 3 mo after HBIG.
Lab Test Interferences None well documented.
Adverse Reactions OTHER Local pain and tenderness at injection site; urticaria; angioedema; anaphylactic reactions.
Precautions
Pregnancy: Category C. Lactation: Undetermined.
|
PATIENT CARE CONSIDERATIONS |
|
Administration/Storage
- Inspect solution for particulate matter and discoloration before administration.
- Administer IM, preferably in gluteal or deltoid muscle in adults and children. In newborns, administer IM in anterolateral thigh. Do not give IV.
- Always record manufacturer’s name and lot number on vial in patient’s permanent record file along with date of administration, name and title of person administering injection.
- Refrigerate vials. Do not freeze.
Assessment/Interventions
- Obtain complete history, including drug history and any known allergies.
- Check patient’s immunization history to verify that administration regimen is being followed.
- Review patient’s medical history for history of serious adverse reactions to previous dose of HBIG.
- Monitor for hypersensitivity or anaphylaxis. Epinephrine should always be available to counteract any possible reactions.
| OVERDOSAGE: SIGNS & SYMPTOMS |
| |
Pain, tenderness |
|
Patient/Family Education
- Instruct parent to vaccinate all at-risk infants as soon after birth as possible and again at 3 mo.
- Instruct patient that therapy is useful as postexposure prophylaxis as soon after exposure as possible (preferably within 7 days.)
- Provide patient or parent with immunization history record and record this injection in patient’s medical records.
- Instruct patient to give analgesic for local pain. Avoid giving aspirin to children.
- Inform parent or patient of schedule for vaccination program if necessary.
Drug Dose ::
| (hep-uh-TIGHT-iss) |
| BayHep B |
| Injection |
| 217 IU/mL |
| Nabi HB |
| Injection |
| 312 IU/mL |
| Bayhep B |
| Class: Immune serum |
Action Directly neutralizes hepatitis B virus.
Indications For passive, transient prevention of hepatitis B infection after viral exposure via needlestick or mucous membrane contact; prevention of hepatitis B in infants born to HBsAg-positive mothers. Most effective when used within 7 days of exposure.
Contraindications None well documented.
Route/Dosage
Adults and Children: IM 0.06 mL/kg (usually 3 to 5 mL). Administer as soon as possible after exposure and repeat 28 to 30 days later. Newborns of HBsAg-Positive Mothers: IM 0.5 mL. Administer first HBIG dose as soon as possible, preferably < 12 hr after birth. Also give hepatitis B vaccine. If hepatitis B vaccine is declined, repeat HBIG at 3 and 6 mo of age.
Interactions
Anticoagulants: Give HBIG with caution to people receiving anticoagulant therapy. Vaccines: To avoid inactivating vaccines containing live viruses (except measles vaccine) or bacteria, give live vaccines 3 mo after HBIG.
Lab Test Interferences None well documented.
Adverse Reactions OTHER Local pain and tenderness at injection site; urticaria; angioedema; anaphylactic reactions.
Precautions
Pregnancy: Category C. Lactation: Undetermined.
|
PATIENT CARE CONSIDERATIONS |
|
Administration/Storage
- Inspect solution for particulate matter and discoloration before administration.
- Administer IM, preferably in gluteal or deltoid muscle in adults and children. In newborns, administer IM in anterolateral thigh. Do not give IV.
- Always record manufacturer’s name and lot number on vial in patient’s permanent record file along with date of administration, name and title of person administering injection.
- Refrigerate vials. Do not freeze.
Assessment/Interventions
- Obtain complete history, including drug history and any known allergies.
- Check patient’s immunization history to verify that administration regimen is being followed.
- Review patient’s medical history for history of serious adverse reactions to previous dose of HBIG.
- Monitor for hypersensitivity or anaphylaxis. Epinephrine should always be available to counteract any possible reactions.
| OVERDOSAGE: SIGNS & SYMPTOMS |
| |
Pain, tenderness |
|
Patient/Family Education
- Instruct parent to vaccinate all at-risk infants as soon after birth as possible and again at 3 mo.
- Instruct patient that therapy is useful as postexposure prophylaxis as soon after exposure as possible (preferably within 7 days.)
- Provide patient or parent with immunization history record and record this injection in patient’s medical records.
- Instruct patient to give analgesic for local pain. Avoid giving aspirin to children.
- Inform parent or patient of schedule for vaccination program if necessary.
Contraindication ::
| (hep-uh-TIGHT-iss) |
| BayHep B |
| Injection |
| 217 IU/mL |
| Nabi HB |
| Injection |
| 312 IU/mL |
| Bayhep B |
| Class: Immune serum |
Action Directly neutralizes hepatitis B virus.
Indications For passive, transient prevention of hepatitis B infection after viral exposure via needlestick or mucous membrane contact; prevention of hepatitis B in infants born to HBsAg-positive mothers. Most effective when used within 7 days of exposure.
Contraindications None well documented.
Route/Dosage
Adults and Children: IM 0.06 mL/kg (usually 3 to 5 mL). Administer as soon as possible after exposure and repeat 28 to 30 days later. Newborns of HBsAg-Positive Mothers: IM 0.5 mL. Administer first HBIG dose as soon as possible, preferably < 12 hr after birth. Also give hepatitis B vaccine. If hepatitis B vaccine is declined, repeat HBIG at 3 and 6 mo of age.
Interactions
Anticoagulants: Give HBIG with caution to people receiving anticoagulant therapy. Vaccines: To avoid inactivating vaccines containing live viruses (except measles vaccine) or bacteria, give live vaccines 3 mo after HBIG.
Lab Test Interferences None well documented.
Adverse Reactions OTHER Local pain and tenderness at injection site; urticaria; angioedema; anaphylactic reactions.
Precautions
Pregnancy: Category C. Lactation: Undetermined.
|
PATIENT CARE CONSIDERATIONS |
|
Administration/Storage
- Inspect solution for particulate matter and discoloration before administration.
- Administer IM, preferably in gluteal or deltoid muscle in adults and children. In newborns, administer IM in anterolateral thigh. Do not give IV.
- Always record manufacturer’s name and lot number on vial in patient’s permanent record file along with date of administration, name and title of person administering injection.
- Refrigerate vials. Do not freeze.
Assessment/Interventions
- Obtain complete history, including drug history and any known allergies.
- Check patient’s immunization history to verify that administration regimen is being followed.
- Review patient’s medical history for history of serious adverse reactions to previous dose of HBIG.
- Monitor for hypersensitivity or anaphylaxis. Epinephrine should always be available to counteract any possible reactions.
| OVERDOSAGE: SIGNS & SYMPTOMS |
| |
Pain, tenderness |
|
Patient/Family Education
- Instruct parent to vaccinate all at-risk infants as soon after birth as possible and again at 3 mo.
- Instruct patient that therapy is useful as postexposure prophylaxis as soon after exposure as possible (preferably within 7 days.)
- Provide patient or parent with immunization history record and record this injection in patient’s medical records.
- Instruct patient to give analgesic for local pain. Avoid giving aspirin to children.
- Inform parent or patient of schedule for vaccination program if necessary.
Drug Precautions ::
| (hep-uh-TIGHT-iss) |
| BayHep B |
| Injection |
| 217 IU/mL |
| Nabi HB |
| Injection |
| 312 IU/mL |
| Bayhep B |
| Class: Immune serum |
Action Directly neutralizes hepatitis B virus.
Indications For passive, transient prevention of hepatitis B infection after viral exposure via needlestick or mucous membrane contact; prevention of hepatitis B in infants born to HBsAg-positive mothers. Most effective when used within 7 days of exposure.
Contraindications None well documented.
Route/Dosage
Adults and Children: IM 0.06 mL/kg (usually 3 to 5 mL). Administer as soon as possible after exposure and repeat 28 to 30 days later. Newborns of HBsAg-Positive Mothers: IM 0.5 mL. Administer first HBIG dose as soon as possible, preferably < 12 hr after birth. Also give hepatitis B vaccine. If hepatitis B vaccine is declined, repeat HBIG at 3 and 6 mo of age.
Interactions
Anticoagulants: Give HBIG with caution to people receiving anticoagulant therapy. Vaccines: To avoid inactivating vaccines containing live viruses (except measles vaccine) or bacteria, give live vaccines 3 mo after HBIG.
Lab Test Interferences None well documented.
Adverse Reactions OTHER Local pain and tenderness at injection site; urticaria; angioedema; anaphylactic reactions.
Precautions
Pregnancy: Category C. Lactation: Undetermined.
|
PATIENT CARE CONSIDERATIONS |
|
Administration/Storage
- Inspect solution for particulate matter and discoloration before administration.
- Administer IM, preferably in gluteal or deltoid muscle in adults and children. In newborns, administer IM in anterolateral thigh. Do not give IV.
- Always record manufacturer’s name and lot number on vial in patient’s permanent record file along with date of administration, name and title of person administering injection.
- Refrigerate vials. Do not freeze.
Assessment/Interventions
- Obtain complete history, including drug history and any known allergies.
- Check patient’s immunization history to verify that administration regimen is being followed.
- Review patient’s medical history for history of serious adverse reactions to previous dose of HBIG.
- Monitor for hypersensitivity or anaphylaxis. Epinephrine should always be available to counteract any possible reactions.
| OVERDOSAGE: SIGNS & SYMPTOMS |
| |
Pain, tenderness |
|
Patient/Family Education
- Instruct parent to vaccinate all at-risk infants as soon after birth as possible and again at 3 mo.
- Instruct patient that therapy is useful as postexposure prophylaxis as soon after exposure as possible (preferably within 7 days.)
- Provide patient or parent with immunization history record and record this injection in patient’s medical records.
- Instruct patient to give analgesic for local pain. Avoid giving aspirin to children.
- Inform parent or patient of schedule for vaccination program if necessary.
Drug Side Effects ::
| (hep-uh-TIGHT-iss) |
| BayHep B |
| Injection |
| 217 IU/mL |
| Nabi HB |
| Injection |
| 312 IU/mL |
| Bayhep B |
| Class: Immune serum |
Action Directly neutralizes hepatitis B virus.
Indications For passive, transient prevention of hepatitis B infection after viral exposure via needlestick or mucous membrane contact; prevention of hepatitis B in infants born to HBsAg-positive mothers. Most effective when used within 7 days of exposure.
Contraindications None well documented.
Route/Dosage
Adults and Children: IM 0.06 mL/kg (usually 3 to 5 mL). Administer as soon as possible after exposure and repeat 28 to 30 days later. Newborns of HBsAg-Positive Mothers: IM 0.5 mL. Administer first HBIG dose as soon as possible, preferably < 12 hr after birth. Also give hepatitis B vaccine. If hepatitis B vaccine is declined, repeat HBIG at 3 and 6 mo of age.
Interactions
Anticoagulants: Give HBIG with caution to people receiving anticoagulant therapy. Vaccines: To avoid inactivating vaccines containing live viruses (except measles vaccine) or bacteria, give live vaccines 3 mo after HBIG.
Lab Test Interferences None well documented.
Adverse Reactions OTHER Local pain and tenderness at injection site; urticaria; angioedema; anaphylactic reactions.
Precautions
Pregnancy: Category C. Lactation: Undetermined.
|
PATIENT CARE CONSIDERATIONS |
|
Administration/Storage
- Inspect solution for particulate matter and discoloration before administration.
- Administer IM, preferably in gluteal or deltoid muscle in adults and children. In newborns, administer IM in anterolateral thigh. Do not give IV.
- Always record manufacturer’s name and lot number on vial in patient’s permanent record file along with date of administration, name and title of person administering injection.
- Refrigerate vials. Do not freeze.
Assessment/Interventions
- Obtain complete history, including drug history and any known allergies.
- Check patient’s immunization history to verify that administration regimen is being followed.
- Review patient’s medical history for history of serious adverse reactions to previous dose of HBIG.
- Monitor for hypersensitivity or anaphylaxis. Epinephrine should always be available to counteract any possible reactions.
| OVERDOSAGE: SIGNS & SYMPTOMS |
| |
Pain, tenderness |
|
Patient/Family Education
- Instruct parent to vaccinate all at-risk infants as soon after birth as possible and again at 3 mo.
- Instruct patient that therapy is useful as postexposure prophylaxis as soon after exposure as possible (preferably within 7 days.)
- Provide patient or parent with immunization history record and record this injection in patient’s medical records.
- Instruct patient to give analgesic for local pain. Avoid giving aspirin to children.
- Inform parent or patient of schedule for vaccination program if necessary.
Drug Mode of Action ::
| (hep-uh-TIGHT-iss) |
| BayHep B |
| Injection |
| 217 IU/mL |
| Nabi HB |
| Injection |
| 312 IU/mL |
| Bayhep B |
| Class: Immune serum |
Action Directly neutralizes hepatitis B virus.
Indications For passive, transient prevention of hepatitis B infection after viral exposure via needlestick or mucous membrane contact; prevention of hepatitis B in infants born to HBsAg-positive mothers. Most effective when used within 7 days of exposure.
Contraindications None well documented.
Route/Dosage
Adults and Children: IM 0.06 mL/kg (usually 3 to 5 mL). Administer as soon as possible after exposure and repeat 28 to 30 days later. Newborns of HBsAg-Positive Mothers: IM 0.5 mL. Administer first HBIG dose as soon as possible, preferably < 12 hr after birth. Also give hepatitis B vaccine. If hepatitis B vaccine is declined, repeat HBIG at 3 and 6 mo of age.
Interactions
Anticoagulants: Give HBIG with caution to people receiving anticoagulant therapy. Vaccines: To avoid inactivating vaccines containing live viruses (except measles vaccine) or bacteria, give live vaccines 3 mo after HBIG.
Lab Test Interferences None well documented.
Adverse Reactions OTHER Local pain and tenderness at injection site; urticaria; angioedema; anaphylactic reactions.
Precautions
Pregnancy: Category C. Lactation: Undetermined.
|
PATIENT CARE CONSIDERATIONS |
|
Administration/Storage
- Inspect solution for particulate matter and discoloration before administration.
- Administer IM, preferably in gluteal or deltoid muscle in adults and children. In newborns, administer IM in anterolateral thigh. Do not give IV.
- Always record manufacturer’s name and lot number on vial in patient’s permanent record file along with date of administration, name and title of person administering injection.
- Refrigerate vials. Do not freeze.
Assessment/Interventions
- Obtain complete history, including drug history and any known allergies.
- Check patient’s immunization history to verify that administration regimen is being followed.
- Review patient’s medical history for history of serious adverse reactions to previous dose of HBIG.
- Monitor for hypersensitivity or anaphylaxis. Epinephrine should always be available to counteract any possible reactions.
| OVERDOSAGE: SIGNS & SYMPTOMS |
| |
Pain, tenderness |
|
Patient/Family Education
- Instruct parent to vaccinate all at-risk infants as soon after birth as possible and again at 3 mo.
- Instruct patient that therapy is useful as postexposure prophylaxis as soon after exposure as possible (preferably within 7 days.)
- Provide patient or parent with immunization history record and record this injection in patient’s medical records.
- Instruct patient to give analgesic for local pain. Avoid giving aspirin to children.
- Inform parent or patient of schedule for vaccination program if necessary.
Drug Interactions ::
| (hep-uh-TIGHT-iss) |
| BayHep B |
| Injection |
| 217 IU/mL |
| Nabi HB |
| Injection |
| 312 IU/mL |
| Bayhep B |
| Class: Immune serum |
Action Directly neutralizes hepatitis B virus.
Indications For passive, transient prevention of hepatitis B infection after viral exposure via needlestick or mucous membrane contact; prevention of hepatitis B in infants born to HBsAg-positive mothers. Most effective when used within 7 days of exposure.
Contraindications None well documented.
Route/Dosage
Adults and Children: IM 0.06 mL/kg (usually 3 to 5 mL). Administer as soon as possible after exposure and repeat 28 to 30 days later. Newborns of HBsAg-Positive Mothers: IM 0.5 mL. Administer first HBIG dose as soon as possible, preferably < 12 hr after birth. Also give hepatitis B vaccine. If hepatitis B vaccine is declined, repeat HBIG at 3 and 6 mo of age.
Interactions
Anticoagulants: Give HBIG with caution to people receiving anticoagulant therapy. Vaccines: To avoid inactivating vaccines containing live viruses (except measles vaccine) or bacteria, give live vaccines 3 mo after HBIG.
Drug Assesment ::
| (hep-uh-TIGHT-iss) |
| BayHep B |
| Injection |
| 217 IU/mL |
| Nabi HB |
| Injection |
| 312 IU/mL |
| Bayhep B |
| Class: Immune serum |
Action Directly neutralizes hepatitis B virus.
Indications For passive, transient prevention of hepatitis B infection after viral exposure via needlestick or mucous membrane contact; prevention of hepatitis B in infants born to HBsAg-positive mothers. Most effective when used within 7 days of exposure.
Contraindications None well documented.
Route/Dosage
Adults and Children: IM 0.06 mL/kg (usually 3 to 5 mL). Administer as soon as possible after exposure and repeat 28 to 30 days later. Newborns of HBsAg-Positive Mothers: IM 0.5 mL. Administer first HBIG dose as soon as possible, preferably < 12 hr after birth. Also give hepatitis B vaccine. If hepatitis B vaccine is declined, repeat HBIG at 3 and 6 mo of age.
Interactions
Anticoagulants: Give HBIG with caution to people receiving anticoagulant therapy. Vaccines: To avoid inactivating vaccines containing live viruses (except measles vaccine) or bacteria, give live vaccines 3 mo after HBIG.
Lab Test Interferences None well documented.
Adverse Reactions OTHER Local pain and tenderness at injection site; urticaria; angioedema; anaphylactic reactions.
Precautions
Pregnancy: Category C. Lactation: Undetermined.
|
PATIENT CARE CONSIDERATIONS |
|
Administration/Storage
- Inspect solution for particulate matter and discoloration before administration.
- Administer IM, preferably in gluteal or deltoid muscle in adults and children. In newborns, administer IM in anterolateral thigh. Do not give IV.
- Always record manufacturer’s name and lot number on vial in patient’s permanent record file along with date of administration, name and title of person administering injection.
- Refrigerate vials. Do not freeze.
Assessment/Interventions
- Obtain complete history, including drug history and any known allergies.
- Check patient’s immunization history to verify that administration regimen is being followed.
- Review patient’s medical history for history of serious adverse reactions to previous dose of HBIG.
- Monitor for hypersensitivity or anaphylaxis. Epinephrine should always be available to counteract any possible reactions.
| OVERDOSAGE: SIGNS & SYMPTOMS |
| |
Pain, tenderness |
|
Patient/Family Education
- Instruct parent to vaccinate all at-risk infants as soon after birth as possible and again at 3 mo.
- Instruct patient that therapy is useful as postexposure prophylaxis as soon after exposure as possible (preferably within 7 days.)
- Provide patient or parent with immunization history record and record this injection in patient’s medical records.
- Instruct patient to give analgesic for local pain. Avoid giving aspirin to children.
- Inform parent or patient of schedule for vaccination program if necessary.
Drug Storage/Management ::
| (hep-uh-TIGHT-iss) |
| BayHep B |
| Injection |
| 217 IU/mL |
| Nabi HB |
| Injection |
| 312 IU/mL |
| Bayhep B |
| Class: Immune serum |
Action Directly neutralizes hepatitis B virus.
Indications For passive, transient prevention of hepatitis B infection after viral exposure via needlestick or mucous membrane contact; prevention of hepatitis B in infants born to HBsAg-positive mothers. Most effective when used within 7 days of exposure.
Contraindications None well documented.
Route/Dosage
Adults and Children: IM 0.06 mL/kg (usually 3 to 5 mL). Administer as soon as possible after exposure and repeat 28 to 30 days later. Newborns of HBsAg-Positive Mothers: IM 0.5 mL. Administer first HBIG dose as soon as possible, preferably < 12 hr after birth. Also give hepatitis B vaccine. If hepatitis B vaccine is declined, repeat HBIG at 3 and 6 mo of age.
Interactions
Anticoagulants: Give HBIG with caution to people receiving anticoagulant therapy. Vaccines: To avoid inactivating vaccines containing live viruses (except measles vaccine) or bacteria, give live vaccines 3 mo after HBIG.
Lab Test Interferences None well documented.
Adverse Reactions OTHER Local pain and tenderness at injection site; urticaria; angioedema; anaphylactic reactions.
Precautions
Pregnancy: Category C. Lactation: Undetermined.
|
PATIENT CARE CONSIDERATIONS |
|
Administration/Storage
- Inspect solution for particulate matter and discoloration before administration.
- Administer IM, preferably in gluteal or deltoid muscle in adults and children. In newborns, administer IM in anterolateral thigh. Do not give IV.
- Always record manufacturer’s name and lot number on vial in patient’s permanent record file along with date of administration, name and title of person administering injection.
- Refrigerate vials. Do not freeze.
Assessment/Interventions
- Obtain complete history, including drug history and any known allergies.
- Check patient’s immunization history to verify that administration regimen is being followed.
- Review patient’s medical history for history of serious adverse reactions to previous dose of HBIG.
- Monitor for hypersensitivity or anaphylaxis. Epinephrine should always be available to counteract any possible reactions.
| OVERDOSAGE: SIGNS & SYMPTOMS |
| |
Pain, tenderness |
|
Patient/Family Education
- Instruct parent to vaccinate all at-risk infants as soon after birth as possible and again at 3 mo.
- Instruct patient that therapy is useful as postexposure prophylaxis as soon after exposure as possible (preferably within 7 days.)
- Provide patient or parent with immunization history record and record this injection in patient’s medical records.
- Instruct patient to give analgesic for local pain. Avoid giving aspirin to children.
- Inform parent or patient of schedule for vaccination program if necessary.
Drug Notes ::
| (hep-uh-TIGHT-iss) |
| BayHep B |
| Injection |
| 217 IU/mL |
| Nabi HB |
| Injection |
| 312 IU/mL |
| Bayhep B |
| Class: Immune serum |
Action Directly neutralizes hepatitis B virus.
Indications For passive, transient prevention of hepatitis B infection after viral exposure via needlestick or mucous membrane contact; prevention of hepatitis B in infants born to HBsAg-positive mothers. Most effective when used within 7 days of exposure.
Contraindications None well documented.
Route/Dosage
Adults and Children: IM 0.06 mL/kg (usually 3 to 5 mL). Administer as soon as possible after exposure and repeat 28 to 30 days later. Newborns of HBsAg-Positive Mothers: IM 0.5 mL. Administer first HBIG dose as soon as possible, preferably < 12 hr after birth. Also give hepatitis B vaccine. If hepatitis B vaccine is declined, repeat HBIG at 3 and 6 mo of age.
Interactions
Anticoagulants: Give HBIG with caution to people receiving anticoagulant therapy. Vaccines: To avoid inactivating vaccines containing live viruses (except measles vaccine) or bacteria, give live vaccines 3 mo after HBIG.
Lab Test Interferences None well documented.
Adverse Reactions OTHER Local pain and tenderness at injection site; urticaria; angioedema; anaphylactic reactions.
Precautions
Pregnancy: Category C. Lactation: Undetermined.
|
PATIENT CARE CONSIDERATIONS |
|
Administration/Storage
- Inspect solution for particulate matter and discoloration before administration.
- Administer IM, preferably in gluteal or deltoid muscle in adults and children. In newborns, administer IM in anterolateral thigh. Do not give IV.
- Always record manufacturer’s name and lot number on vial in patient’s permanent record file along with date of administration, name and title of person administering injection.
- Refrigerate vials. Do not freeze.
Assessment/Interventions
- Obtain complete history, including drug history and any known allergies.
- Check patient’s immunization history to verify that administration regimen is being followed.
- Review patient’s medical history for history of serious adverse reactions to previous dose of HBIG.
- Monitor for hypersensitivity or anaphylaxis. Epinephrine should always be available to counteract any possible reactions.
| OVERDOSAGE: SIGNS & SYMPTOMS |
| |
Pain, tenderness |
|
Patient/Family Education
- Instruct parent to vaccinate all at-risk infants as soon after birth as possible and again at 3 mo.
- Instruct patient that therapy is useful as postexposure prophylaxis as soon after exposure as possible (preferably within 7 days.)
- Provide patient or parent with immunization history record and record this injection in patient’s medical records.
- Instruct patient to give analgesic for local pain. Avoid giving aspirin to children.
- Inform parent or patient of schedule for vaccination program if necessary.
Disclaimer ::
The Information available on this site is for only Informational Purpose , before any use of this information please consult your Doctor .Price of the drugs indicated above may not match to real price due to many possible reasons may , including local taxes etc.. These are only approximate indicative prices of the drug.
